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ABSTRACT
Objective: Felodipine, a BCS class II calcium channel blocker, is used in the management of hypertension and angina pectoris. Due to the poor solubility 
and low bioavailability of the drug, there is a necessity to design an alternative route to achieve a constant plasma concentration of felodipine for its 
maximum therapeutic utility and can be achieved by transdermal route.
Methods: In this study, matrix type transdermal patches were prepared using different combinations of hydrophilic polymer, namely, 
polyvinylpyrrolidone (PVP) and hydrophobic polymer, namely, ethyl cellulose (EC) by solvent evaporation technique and were subjected for 
characterization.
Results: The Fourier transform infrared studies confirmed the compatibility between drug and polymers. Hydrophilic nature of the polymers 
greatly influenced physical characteristics and dissolution rate. Equal percentage of PVP and EC yielded patches with good folding endurance. The 
concentration of plasticizer present in the patches gave them desired folding endurance, and it increased with the presence of hydrophilic polymer. 
The formulation with highest PVP concentration, F3, exhibited a maximum drug release of 96.23% for 24 hrs. While the formulation with highest EC 
concentration, F5, exhibited only 74.45% drug release for 24 hrs.
Conclusion: From the data, formulation F2 (PVP/EC, 2:1) can be concluded as best formulation due to its desired physical characteristics, good initial 
drug release, sustained release behavior, and good in vitro permeation. This formulation can be further studied in a clinical scenario.
Keywords: Calcium channel blocker, Felodipine, Transdermal, Permeation.
INTRODUCTION
Sustained release preparations were developed intended to provide 
prolonged drug release than the conventional dosage forms. In 
prolonged treatment of hypertension (high blood pressure), they are 
highly recommended and commercially available mostly in the form 
of conventional tablets [1]. An approach to sustained delivery of a 
therapeutically active agent is transdermal drug delivery system [2]. 
They provide relatively constant plasma drug concentrations, avoiding 
the peaks and valleys associated with conventional dosage forms. They 
also offer advantages such as decrease in frequency of administration, 
avoiding first-pass metabolism, reducing gastrointestinal side 
effects, and improving patient compliance [3]. Skin is the most 
magnanimous and readily accessible organ of human body and is used 
as an administration site of drug for both local and systemic actions; 
the highly organized structure of stratum corneum forms an effective 
barrier to the permeation of poorly penetrating drugs [4-6].
Felodipine, BCS class II drug, a calcium channel blocker is primarily 
used to treat hypertension and also used in the treatment of angina, 
arrhythmia, and coronary vasospasm [7]. It acts by inhibiting the influx 
of calcium in smooth muscle cells and prevents calcium-dependent 
myocyte contraction and vasoconstriction. Due to its low bioavailability 
and short half-life, it needs to be frequently administered creating 
patient incompliance [8]. It possesses ideal characteristics for being 
formulated as transdermal patch, such as low molecular weight 
(384.25), low dose (5 mg), and low solubility and bioavailability (15%), 
and undergoes extensive first-pass metabolism [9].
The objective of the present study is to fabricate a novel transdermal 
delivery system for treating hypertension, which achieves a prolonged 
drug release and effective management of hypertension, while at the 
same time by reducing the frequency and dose of administration. The 
objective includes designing more patient friendly delivery system of 




Felodipine was obtained from Orchid Chemicals and Pharmaceuticals 
Ltd. as a gift sample. Ethyl cellulose (EC), polyvinylpyrrolidone (PVP), 
and polyvinyl alcohol (PVA) were procured from Sigma Aldrich, Mumbai, 
India, and all other chemicals and reagents used were of analytical grade.
Determination of partition coefficient
Shake-flask method was employed to determine the partition 
coefficient of the drug using n-octanol and phosphate buffer pH 7.4 as 
oil and water phases, respectively. Equal quantities of two phases were 
taken in a separating funnel. A known quantity of felodipine was added 
and shaken for 10 minutes and allowed to stand for an hour. Aqueous 
and oil phases were separated and filtered through Whatman filter 
paper. The samples were analyzed for drug content in each phase. The 
partition coefficient ko/w was calculated using the formula. Triplicate 








Compatibility studies of felodipine and the polymers were carried out 
using Fourier transform infrared (FTIR) spectroscopy. Spectroscopy of 
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the samples was obtained in the range of 4000/cm to 400/cm using 
a PerkinElmer-FTIR 8201 PC spectrophotometer by the KBr disc 
method [12].
Preparation of transdermal patches
Different ratios (Table 1) of PVP and EC were taken in the open-ended 
cylindrical glass molds to prepare the matrix type transdermal patches 
of felodipine. Backing membrane was cast by pouring 4% w/v of PVA 
solution in the molds previously wrapped with aluminum foil. It was 
allowed to dry at 60°C in hot air oven for 6 hrs. The two polymers 
were taken in requisite ratio and dissolved in chloroform. Di-n-butyl 
phthalate was taken in 30% w/w of polymer composition and used 
as plasticizer. Drug was added, 20% w/w of polymer composition, to 
form homogenous dispersion with plasticizer and polymers. Three 
milliliters of dispersion were cast on previously prepared PVA backing 
membrane and dried at 40°C for 6 hrs. The prepared patches were kept 
in desiccators until used [13].
Thickness
Thickness of both the backing membrane and patch was measured 
using digital calipers. The average thicknesses of the backing membrane 
and the whole patch were determined [14,15]. The average thickness 
of the adhesive matrix containing the drug was determined using the 
following equation:
Thickness of adhesive matrix=Thickness of whole patch−Thickness of 
backing membrane
Moisture content
The prepared patches were weighed individually and kept in a 
desiccator containing activated silica at room temperature for 24 hrs. 
The individual films were weighed again until it showed a constant 






The patches were weighed and kept in a desiccator at normal room 
temperature for 24 hrs. This patch was taken out and exposed to 84% 
RH (saturated solution of potassium chloride) in a desiccator. After 
3 days, the patches were taken out and weighed [17]. The percentage of 
moisture uptake was calculated as:
%Moistureuptake






In vitro drug release study
In vitro drug release study was performed using  US Pharmacopeia 
Type V dissolution apparatus (Paddle over disc). The patches were 
placed in between the stainless steel discs (of which one side is mesh 
and one side is plate stainless steel disc, meant for transdermal study). 
To the stainless steel plate, the backing membrane was attached with 
a double-sided adhesive tape so that drug releases from one side only. 
The drug release study was performed at 37±0.5°C and 50 in dissolution 
jar holding 900 ml of 20% v/v polyethylene glycol (PEG) 400 in normal 
saline as dissolution medium. A 5 ml of sample was withdrawn at 
regular time intervals and replaced with 5 ml of 20%v/v PEG400 in 
normal saline. The samples were analyzed to calculate the quantity of 
drug released. The mean cumulative amount of drug released of patch 
was plotted against time [18].
Ex vivo permeation
Franz diffusion cell was used to study the permeation of transdermal 
patch. Full thickness of rat abdominal epidermis was mounted onto a 
Franz diffusion cell. Place the patch in such a way that stratum corneum 
side of rat skin was in contact with transdermal patch in the donor 
compartment and the dermis side was in constant contact with the 
receptor solution. The receptor compartment was filled with 20% v/v 
PEG 400 in normal saline and stirred magnetically. A 1 ml of sample was 
withdrawn at different time intervals and analyzed for drug content and 
replaced with an equal volume of 20% v/v PEG 400 in normal saline 
at each time interval. The cumulative amount of drug permeated was 
calculated for 12 hrs and plotted against time [19].
Statistical analysis
All data were represented as the mean ± standard deviation. The 
graphs and error bars were depicted using GraphPad Prism 5 software 
(GraphPad Software, Inc., San Diego, CA).
RESULTS AND DISCUSSION
To determine the drug partition coefficient between skin and in vitro 
study fluid, octanol and phosphate buffer pH 7.4 were considered to be 
a standard system. The studies were conducted in triplicate. The mean 
value of all these experiments was considered as partition coefficient. 
The log P of felodipine was found to be 4.46. The log P clearly indicates 
that felodipine possesses optimum lipophilic nature to be formulated 
into a transdermal delivery system.
The spectrum of pure drug shows absorption band at 3389/cm due 
to the stretching N-H group of dihydropyridine moiety. The band 
between 2946/cm and 3070/cm was due to stretching aromatic and 
aliphatic C-H bond. The absorption band at 1694/cm can be attributed 
to carbonyl group present on the side chain of dihydropyridine moiety. 
The band at 1495/cm was due to aromatic C=C bond. The bands 
present at 1204/cm indicate C=O stretching. The spectrum of the 
mixture showed that they were in good agreement with the spectra of 
felodipine. Thus, from the spectra in Fig. 1, it was understood that  there 
was no significant interaction between felodipine and polymers used in 
the preparation of transdermal patches.
PVP and EC combination was also preferred in preparation of 
transdermal patches for sustaining the release of diclofenac [20]. 
The transdermal patches for felodipine were analyzed for various 
physical characterizations such as moisture content, moisture uptake, 
thickness, and folding endurance. The summary of the characterization 
parameters was given in Table 2. The moisture content and moisture 
uptake studies on patches revealed that an increase in the concentration 
of PVP resulted in high moisture content and high moisture uptake 
ability (Fig. 2).
On the other hand, the formulations exhibited, increasing the EC 
proportion resulted in patches with low moisture uptake ability. This 
can be attributed to the hydrophilic nature of PVP and hydrophobic 
Table 1: Formulation of transdermal patches
Formulation code Ratio of PVP:EC Total weight of PVP 
and EC (mg)
Chloroform (ml) Di‑n‑butyl 
phthalate (ml)
Felodipine (mg)
F1 1:1 250 10 30% w/w of polymers 20% w/w of polymers
F2 2:1 250 10 30% w/w of polymers 20% w/w of polymers
F3 5:1 250 10 30% w/w of polymers 20% w/w of polymers
F4 1:2 250 10 30% w/w of polymers 20% w/w of polymers
F5 1:5 250 10 30% w/w of polymers 20% w/w of polymers
PVP: Polyvinylpyrrolidone, EC: Ethyl cellulose
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nature of EC. At the same time, the patches with more PVP percentage 
also seen to be thicker than that of patches with more EC percentage. 
Low moisture content in the formulations maintains the stability and 
protects the film from being completely dried. It also protects the 
patches from being susceptible to microbial contamination and also 
yields thin patches [21]. The patches with high moisture content were 
observed to be bulky and thicker. Thickness of the patch is an important 
criteria which gives more patient compliance [22]. Weight variation 
was observed to be negligible and helped to maintain the uniformity of 
dose. By increasing the percentage of PVP, a higher folding endurance 
was observed and it decreased with increasing the percentage of 
hydrophobic polymer (EC). Equal percentage of PVP and EC yielded 
patches with good folding endurance. The concentration of plasticizer 
present in the patches gave them desired folding endurance, and it 
increased with the presence of hydrophilic polymer.
In vitro drug release is an important tool to predict the in vivo behavior 
of drug [23]. Table 3 shows the release profiles of patches carried out 
for 24 hrs. In the formulation F3, which had highest percentage of PVP, 
a maximum drug release of 96.23% was seen at the end of 24 hrs. In 
the formulations, F2 and F3, an initial burst release was observed. PVP 
reduced the crystalline nature of felodipine and resulted in increased 
drug release. The rate of release was decreased with decreasing 
proportion of PVP and increasing proportion of EC. The formulation 
F5 which contains maximum EC concentration exhibited lowest drug 
release of 74.45%, and their dissolution profile is depicted in Fig. 3. 
This clearly indicates the sustained release behavior of EC due to its 
hydrophobic nature. The patches containing equal amounts of PVP and 
EC exhibited a good drug release of 80.24% which can be helpful in 
maintain a stable plasma concentration.
Ex vivo permeation studies are a predictive assessment of in vivo 
performance of drug. The cumulative amount of drug permeated after 
12 hrs was calculated and was given in Table 4. A maximum permeation 
of 76.83% was observed in the formulation F3, which had a maximum 
proportion of PVP. This result clearly indicates that an increase in 
hydrophilic polymer (PVP) in the patch increases the skin permeation 
of the drug. Increase in the concentration of hydrophobic polymer 
(EC) inhibited the drug permeation. This can be clearly noticed from 
the formulation containing maximum amount of EC, F5, allowed only 
43.35% of drug to permeate after 12 hrs of study. About 60.83% of drug 
Fig. 1: Fourier transform infrared spectra of felodipine and 
physical mixtures
Table 2: Physical characterization of transdermal patches
Formulation code Folding endurance* Thickness* (mm) Percentage moisture content* (%) Percentage moisture uptake* (%)
F1 177±12 0.189±0.25 5.90±0.10 11.28±0.01
F2 189±31 0.201±0.98 7.36±0.12 12.33±0.12
F3 223±15 0.240±0.23 8.01±0.05 16.91±0.05
F4 171±18 0.199±0.73 3.46±0.29 6.38±0.26
F5 169±09 0.233±0.59 1.28±0.06 4.79±0.21
*Data were presented as mean±standard deviation (n=6)
Table 3: In vitro dissolution profile of transdermal patches
Time (hrs) Cumulative drug release (%)
F1 F2 F3 F4 F5
0.5 6.02±1.13 12.21±1.51 15.60±1.09 4.25±1.83 4.28±1.52
1 12.08±2.26 23.02±1.62 24.21±1.50 11.56±1.12 8.65±1.93
2 29.23±1.39 37.29±1.43 34.23±1.46 19.24±1.72 13.47±1.27
4 36.89±1.42 41.35±2.30 53.24±1.77 32.29±2.38 26.02±2.48
8 50.35±2.16 54.24±1.19 68.03±3.33 48.89±1.55 43.09±1.61
12 62.64±2.96 76.21±1.25 79.56±2.17 53.32±1.42 48.32±1.17
24 80.24±1.48 92.37±2.19 96.23±2.28 60.65±1.50 55.45±2.58
Data were presented as mean±standard deviation (n=6)
Fig. 2: Moisture studies on transdermal patches. Data are 
presented as mean±standard deviation (n=6)
Table 4: Ex vivo skin permeation studies






Data were presented as mean±standard deviation (n=6)
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permeation was seen in the formulation F1, which had equal proportion 
of hydrophilic and hydrophobic polymers.
CONCLUSION
EC and PVP combination can be used to prepare the transdermal 
patches of felodipine or other calcium channel blockers. The prepared 
patches are capable of surmounting the low bioavailability factor 
associated with oral administration of felodipine. From the data, 
formulation F2 (PVP/EC, 2:1) can be concluded as best formulation due 
to its desired physical characteristics, sustained release behavior, and 
good in vitro permeation. This formulation can be further studied in a 
clinical scenario.
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